Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment

Journal of Immunology

Volumn 188, Issue 9, 2012, Pages 4405-4411

  Warncke, Max ^a   Calzascia, Thomas ^a   Coulot, Michele ^a   Balke, Nicole ^a   Touil, Ratiba ^a   Kolbinger, Frank ^a   Heusser, Christoph ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD20 ANTIGEN; CD40 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; RITUXIMAB;

ADAPTATION; ALLOTYPE; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CELL FUNCTION; CONTROLLED STUDY; EFFECTOR CELL; GRANULOCYTE; HUMAN; MOLECULAR GENETICS; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING;

ANIMALS; BASE SEQUENCE; GPI-LINKED PROTEINS; GRANULOCYTES; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MOLECULAR SEQUENCE DATA; RECEPTORS, IGG; SPECIES SPECIFICITY;

EID: 84860330201     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200090     Document Type: Article

References (45)

1. Heusser, C. H., C. L. Anderson, and H. M. Grey. 1977. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 145: 1316-1327. (Pubitemid 8105374)
2. Unkeless, J. C. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J. Exp. Med. 150: 580-596. (Pubitemid 9250687)
3. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290. (Pubitemid 32368037)
4. van de Winkel, J. G., and P. J. Capel. 1993. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 14: 215-221. (Pubitemid 23124515)
5. Jiang, X. R., A. Song, S. Bergelson, T. Arroll, B. Parekh, K. May, S. Chung, R. Strouse, A. Mire-Sluis, and M. Schenerman. 2011. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 10: 101-111.
6. Ravetch, J. V., and J. P. Kinet. 1991. Fc receptors. Annu. Rev. Immunol. 9: 457-492.
7. Daëron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15: 203-234. (Pubitemid 27169280)
8. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310: 1510-1512. (Pubitemid 41746349)
9. Chapman, K., N. Pullen, M. Graham, and I. Ragan. 2007. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat. Rev. Drug Discov. 6: 120-126. (Pubitemid 46745340)
10. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028. (Pubitemid 44343545)
11. Nguyen, D. H., N. Hurtado-Ziola, P. Gagneux, and A. Varki. 2006. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103: 7765-7770.
12. Waibler, Z., L. Y. Sender, C. Merten, R. Hartig, S. Kliche, M. Gunzer, P. Reichardt, U. Kalinke, and B. Schraven. 2008. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One 3: e1708.
13. Eastwood, D., L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings. 2010. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161: 512-526.
14. Hanke, T., M. Trischler, and C. Guntermann. 2006. Superagonistic anti-CD28 antibody. Tegenero AG, WO 20061050949, DE.
15. Hansel, T. T., H. Kropshofer, T. Singer, J. A. Mitchell, and A. J. George. 2010. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9: 325-338.
16. Barrett, D. J., and E. M. Ayoub. 1986. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63: 127-134. (Pubitemid 16196411)
17. Yount, W. J., M. M. Dorner, H. G. Kunkel, and E. A. Kabat. 1968. Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers. J. Exp. Med. 127: 633-646.
18. Aldrich, T., W. Shen, F. Jacobsen, A. Morris, and M. Allen. 2005. Monkey Immunoglobulin Sequences. Amgen, WO 20051047325.
19. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445. (Pubitemid 24030569)
20. Jacobsen, F. W., R. Padaki, A. E. Morris, T. L. Aldrich, R. J. Armitage, M. J. Allen, J. C. Lavallee, and T. Arora. 2011. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J. Immunol. 186: 341-349.
21. Rogers, K. A., F. Scinicariello, and R. Attanasio. 2006. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177: 3848-3856. (Pubitemid 44359919)
22. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
23. Koene, H. R., M. Kleijer, J. Algra, D. Roos, A. E. von dem Borne, and M. de Haas. 1997. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90: 1109-1114. (Pubitemid 27314146)
24. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276: 6591-6604.
25. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2 - A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406: 267-273. (Pubitemid 30604397)
26. Chappel, M. S., D. E. Isenman, M. Everett, Y. Y. Xu, K. J. Dorrington, and M. H. Klein. 1991. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci. USA 88: 9036-9040. (Pubitemid 21915563)
27. van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W. K. Bleeker, P. Martínez-Martínez, E. Vermeulen, T. H. den Bleker, L. Wiegman, T. Vink, L. A. Aarden, et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557. (Pubitemid 47417435)
28. Aalberse, R. C., and J. Schuurman. 2002. IgG4 breaking the rules. Immunology 105: 9-19. (Pubitemid 34128035)
29. Vugmeyster, Y., K. Howell, K. McKeever, D. Combs, and E. Canova-Davis. 2003. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int. Immunopharmacol. 3: 1477-1481. (Pubitemid 37025728)
30. Coxon, A., X. Cullere, S. Knight, S. Sethi, M. W. Wakelin, G. Stavrakis, F. W. Luscinskas, and T. N. Mayadas. 2001. Fc gamma RIII mediates neutrophil recruitment to immune complexes: a mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity 14: 693-704. (Pubitemid 32592417)
31. Kimberly, R. P., J. W. Ahlstrom, M. E. Click, and J. C. Edberg. 1990. The glycosyl phosphatidylinositol-linked Fc gamma RIIIPMN mediates transmem-brane signaling events distinct from Fc gamma RII. J. Exp. Med. 171: 1239-1255. (Pubitemid 20120145)
32. Carballido, J. M., N. Carballido-Perrig, A. Oberli-Schrämmli, C. H. Heusser, and K. Blaser. 1994. Regulation of IgE and IgG4 responses by allergen specific T-cell clones to bee venom phospholipase A2 in vitro. J. Allergy Clin. Immunol. 93: 758-767.
33. Maizels, R. M. 2009. Exploring the immunology of parasitism: from surface antigens to the hygiene hypothesis. Parasitology 136: 1549-1564.
34. Scinicariello, F., C. N. Engleman, L. Jayashankar, H. M. McClure, and R. Attanasio. 2004. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 111: 66-74. (Pubitemid 38091051)
35. Stubenrauch, K., U. Wessels, J. T. Regula, H. Kettenberger, J. Schleypen, and U. Kohnert. 2010. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab. Dispos. 38: 84-91.
36. Vugmeyster, Y., K. Howell, A. Bakshl, C. Flores, and E. Canova-Davis. 2003. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 52: 101-109. (Pubitemid 37521508)
37. Stein, M. P., J. C. Edberg, R. P. Kimberly, E. K. Mangan, D. Bharadwaj, C. Mold, and T. W. Du Clos. 2000. C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J. Clin. Invest. 105: 369-376. (Pubitemid 30094457)
38. Agrawal, A., P. P. Singh, B. Bottazzi, C. Garlanda, and A. Mantovani. 2009. Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 653: 98-116.
39. Veri, M. C., S. Burke, L. Huang, H. Li, S. Gorlatov, N. Tuaillon, G. J. Rainey, V. Ciccarone, T. Zhang, K. Shah, et al. 2010. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62: 1933-1943.
40. Horton, H. M., S. Y. Chu, E. C. Ortiz, E. Pong, S. Cemerski, I. W. Leung, N. Jacob, J. Zalevsky, J. R. Desjarlais, W. Stohl, and D. E. Szymkowski. 2011. Antibody-mediated coengagement of FcgRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. 186: 4223-4233.
41. Chu, S., J. Yup, R. Desjarlais, S. Karki, G. Bahadur, A. Lazar, and I. Vostiar. 2008. Methods and compositions for inhibiting CD32b expressing cells. Xencor, WO 20081150494.
42. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
43. Ferrara, C., F. Stuart, P. Sondermann, P. Brünker, and P. Umaña. 2006. The carbohydrate at FcgammaRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281: 5032-5036. (Pubitemid 43847767)
44. Mössner, E., P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, A. Nopora, E. van Puijenbroek, et al. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402.
45. Shibata-Koyama, M., S. Iida, H. Misaka, K. Mori, K. Yano, K. Shitara, and M. Satoh. 2009. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp. Hematol. 37: 309-321.